HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
Read original at benzingaStocks · News reference
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 1:57 PM
- Checked
- Aug 11, 2026, 1:57 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same
Read original at benzinga8-K filing — ALUMIS INC. (ALMS)
Filed: 2026-08-13 AccNo: 0001847367-26-000016 Size: 356 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar